Return to homepagePandemic Pact

Global Antimicrobial Resistance Innovation Fund (GAMRIF) - GARDP Core Funding

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), Foreign, Commonwealth & Development Office (FCDO)
  • Total publications:0 publications

Grant number: GB-GOV-10-GAMRIF-WP6-GARDP-CORE

Grant search

Key facts

  • Disease

    Unspecified

  • Start & end year

    2020
    2020

  • Known Financial Commitments (USD)

    $107,222,697

  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), Foreign, Commonwealth & Development Office (FCDO)

  • Principal Investigator

    N/A

  • Research Location

    Switzerland

  • Lead Research Institution

    Global Antibiotic Research and Development Partnership

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership. It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP'Äôs core activities. DHSC will provide unearmarked, core funding to GARDP to support the development and delivery of new treatments for drug-resistant infections that pose the greatest threat to health, with GARDP having a primary focus to enable distribution of treatments to people in low- and middle-income countries and with antimicrobial resistance (AMR) recognised by the UN General Assembly as critical to achieving the Sustainable Development Goals (SDGs).